

AMENDMENTS TO THE CLAIMS

1. (Canceled) An isolated polypeptide comprising an amino acid sequence selected from the group consisting of at least one of

SEQ ID NO.: 2, SEQ ID NO.: 4 and SEQ ID NO.: 6

for use as a medicament.

59. (New) An immunogenic composition comprising an amount of an isolated polypeptide effective for inducing an immune response against *Plasmodium falciparum* parasites in a mammalian subject and a pharmaceutically acceptable carrier, wherein the isolated polypeptide comprises at least one amino acid sequence selected from the group consisting of:

- (a) SEQ ID NO:2, SEQ ID NO:4, and SEQ ID NO:6;
- (b) a sequence having at least 80% sequence identity to SEQ ID NO:2, SEQ ID NO:4 or SEQ ID NO:6;
- (c) a sub-sequence of the sequences in (a) or (b), wherein the sub-sequence has a minimum length of 10 amino acids; and
- (d) a sub-sequence of the sequences in (a) or (b), wherein the sub-sequence comprises at least one B-cell epitope or at least one T-cell epitope.

60. (New) A method for inducing an immune response against *Plasmodium falciparum* parasites in a mammalian subject, comprising administering to a mammalian subject an amount of an immunogenic composition effective to induce an immune response against *Plasmodium falciparum* parasites in the mammalian subject, wherein the immunogenic composition comprises an isolated polypeptide which comprises at least one amino acid sequence selected from the group consisting of:

- (a) SEQ ID NO:2, SEQ ID NO:4, and SEQ ID NO:6;
- (b) a sequence having at least 80% sequence identity to SEQ ID NO:2, SEQ ID NO:4 or SEQ ID NO:6;

(c) a sub-sequence of the sequences in (a) or (b), wherein the sub-sequence has a minimum length of 10 amino acids; and

(d) a sub-sequence of the sequences in (a) or (b), wherein the sub-sequence comprises at least one B-cell epitope or at least one T-cell epitope.

61. (New) The methods of Claim 60, wherein the immune response prophylactically or therapeutically reduces the incidence, prevalence or severity of malaria in the mammalian subject.

62. (New) A method for prophylactically or therapeutically reducing the incidence, prevalence or severity of malaria in a mammalian subject, comprising administering to a mammalian subject an amount of an immunogenic composition effective to prophylactically or therapeutically reduce the incidence, prevalence or severity of malaria in the mammalian subject, wherein the immunogenic composition comprises an isolated polypeptide which comprises at least one amino acid sequence selected from the group consisting of:

(a) SEQ ID NO:2, SEQ ID NO:4, and SEQ ID NO:6;

(b) a sequence having at least 80% sequence identity to SEQ ID NO:2, SEQ ID NO:4 or SEQ ID NO:6;

(c) a sub-sequence of the sequences in (a) or (b), wherein the sub-sequence has a minimum length of 10 amino acids; and

(d) a sub-sequence of the sequences in (a) or (b), wherein the sub-sequence comprises at least one B-cell epitope or at least one T-cell epitope.